Israel-based Tel Aviv University (TAU)’s technology transfer company Ramot has entered a research and licence agreement with Swiss-based biopharmaceutical company Neovii to develop a vaccine against Covid-19.
As part of the alliance, Neovii will collaborate with a research team led by TAU’s School of Molecular Cell Biology and Biotechnology professor Jonathan Gershoni.
The deal provides the Swiss company with the exclusive right to develop and commercialise a platform technology created by Gershoni to rapidly identify epitope-based vaccines.
TAU and Neovii aim to develop a Covid-19 vaccine that could reconstruct the coronavirus’ receptor binding motif (RBM), an important structure of ‘spike’ protein of the virus.